ORDERED, ADJUDGED, AND DECREED as follows: 1. This Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties for purposes of this action only, including as set fmth below in Paragraph 6 of this Consent Judgment. 2. As used in this Consent Judgment, the term "Defendant ANDA Product" shall mean a drug product manufactured, impmted, sold, offered for sale, marketed, or disti'ibuted pursuant to Abbreviated New Drug Application No. 220937 in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico.As used in this Consent Judgment, the term "Patents-in-Suit" shall mean U.S. Patent Nos. 8,293,742, 9,259,425, 11,596,600, and 11,833,245. 4. Until expiration of the Patents-in-Suit, Defendant, including any of its successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party on its behalf, by making, having made, using, selling, offering to sell, impo1iing, or distributing of the Defendant ANDA Product in or for the United States of America, unless and to the extent othe1wise specifically authorized by Plaintiffs, and is further enjoined from assisting or cooperating with any third parties in connection with any infringement of the Patents-in-Suit by any such third patiies in connection with making, having made, using, selling, offering to sell, importing, or distributing of any brimonidine tartrate 0.025% ophthalmic solution that references NDA208144 in or for the United States of America, unless and to the extent otherwise specifically authorized by Plaintiffs. 5. Compliance with this Consent Judgment may be enforced by Plaintiffs and their respective successors in interest or assigns. 6. This Court retains jurisdiction to enforce the terms of this Consent Judgment and to enforce and resolve any disputes related thereto. 7. All claims, counterclaims, affirmative defenses, motions and petitions asserted in this Action are hereby dismissed without prejudice and without costs, disbursements or attorneys' fees to any patiy. 8. Nothing herein prohibits or is intended to prohibit Defendant from maintaining any "Paragraph IV Certification" pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit.Nothing herein prohibits or is intended to prohibit Defendant from engaging in any activity permitted under 35 U.S.C. § 271(e)(l). 10. Nothing herein restricts or is intended to restrict the U.S. Food and Dmg Administration from approving Abbreviated New Drug Application No. 220937 or the ANDA Product.